Physician profile

Sandra Gilley

Pulmonary Disease · Birmingham, AL

NPI 1235342718

$8,268.99

in general payments reported to CMS, 2019-2025

46 companies · $105 in 2025

The $105 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,379.81

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $1,575.55 2019-2023 Trelegy Ellipta, Arexvy, Nucala
Astrazeneca Pharmaceuticals LP $1,219.10 2019-2023 Fasenra, Tezspire, Breztri
Regeneron Healthcare Solutions, INC. $964.82 2019-2023 Dupixent
Grifols USA, LLC $534.17 2019-2023 Prolastin-C Liquid
Boehringer Ingelheim Pharmaceuticals, INC. $532.31 2019-2023 Ofev
Mallinckrodt Hospital Products INC. $429.12 2020-2023 Acthar
Electromed, INC. $327.44 2019-2023 Smartvest
Genentech USA, INC. $314.73 2019-2023 Xolair
Inspire Medical Systems, INC. $300.53 2021
Actelion Pharmaceuticals US, INC. $175.65 2019-2023 Uptravi, Opsumit
Insmed, INC. $164.78 2019-2020
Gilead Sciences, INC. $153.60 2021-2024
Amgen INC. $133.75 2022-2025 Tezspire
Harmony Biosciences LLC $112.57 2020-2023 Wakix
Takeda Pharmaceuticals U.S.A., INC. $107.67 2020-2023 Glassia
Show all 46 companies
CompanyGeneral paymentsYearsTop products
Genzyme Corporation $101.82 2019-2022
Intuitive Surgical, INC. $94.12 2022
Boston Scientific Corporation $85.74 2025 Ranger
Philips North America LLC $83.15 2019-2020
Mallinckrodt Enterprises LLC $83.03 2019
Jazz Pharmaceuticals INC. $81.70 2019-2021
Abbvie INC. $78.70 2021-2022
Octapharma USA, INC. $62.52 2021
Axsome Therapeutics, INC. $58.99 2023 Sunosi
Shire North American Group INC $50.94 2019
Astellas Pharma US INC $47.45 2019-2023 Cresemba
Pfizer INC. $44.64 2019-2023
Ani Pharmaceuticals, INC. $41.01 2022
Genentech, INC. $38.00 2019
La Jolla Pharmaceutical Company $31.78 2022
Mylan Specialty L.P. $31.54 2021
Csl Behring $19.41 2019
Baxter Healthcare $18.89 2022
Janssen Pharmaceuticals, INC $18.38 2019
Fisher & Paykel Healthcare INC $18.20 2022
Inogen, INC. $16.83 2022
Olympus America INC. $14.90 2021
Pulmonx Corporation $14.23 2023 Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console
Teva Pharmaceuticals USA, INC. $14.12 2019
Idorsia Pharmaceuticals US INC $12.92 2022
Paratek Pharmaceuticals, INC. $12.12 2021
Optinose US, INC. $12.07 2019
Aytu Biopharma, INC. $12.03 2020
Allergan, INC. $12.00 2019
Biomerieux INC $9.47 2019
United Therapeutics Corporation $2.50 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sandra Gilley

$8,268.99

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $105 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/147285/sandra-gilley

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.